Posts Tagged ‘NY Times’

Shining the light on Vitamin D

Thursday, January 6th, 2011
It’s pretty common knowledge by now that sun on human skin leads to the production of Vitamin D, which has been touted for reducing the risk of everything from Type 2 Diabetes to many cancers.  So, with science’s increased recommendations to avoid the sun and increase regular use of sunscreen there has been some concern that we would have a deficit of this nutrient. Not only is this concern unjustified, it is a slippery slope to rationalizing the “need” for a tan. For example, an article in Allure Magazine, which I wrote about recently, discussed the dangers of tanning.
But one young woman, “Katie_k”, who posted a comment, had convinced herself that her tanning salon use was justified by the need for Vitamin D.    Here’s what I wrote to her in response:

This article is important.   And to Katie_k who vowed to continue using tanning beds out of concern about low Vitamin D scares:   My answer? You’re wrong. The fact is, we can now check our  vitamin D level and take supplements should we be found to be deficient.  Skin cancer is nothing to be messed with. Exposing ourselves to a carcinogen like UV rays is never a good idea. Using a tanning bed is especially a bad one.

I am concerned about the Katie_ks of the world. So here’s a reminder from a good summary article, to try again to allay fears about a lack of Vitamin D:

“For most children, teens and adults, a daily dose of 400 international units (IUs) of the vitamin is sufficient, and 600 IUs are recommended. Seniors older than 70 should ideally receive 800 IUs of vitamin D a day, the panel determined. For babies younger than 1, the panel considered 400 IUs of vitamin D enough.

Those levels are somewhat higher than the ones set in 1997, the last time a government panel examined vitamin D intake. But they are far below what many doctors and supplement advocates had been urging….

Does that mean I should give up my vitamin D supplements?

Maintaining a healthy level of vitamin D through diet alone has become much easier since manufacturers began fortifying foods with the nutrient. Fortified foods — including virtually all milk, many brands of orange juice, and some cheeses, yogurts, margarines and breakfast cereals — are now some of the richest dietary sources of vitamin D. High levels exist naturally in fatty fish such as tuna, salmon and mackerel, and it’s also present in egg yolks and beef liver….

Indeed, the sun is a free, plentiful source of vitamin D. When the sun shines on human skin for at least five to 15 minutes, the body produces the nutrient. But with people spending more time indoors and using sunscreen to prevent skin cancer, this source has fallen on hard times. In fact, the panel didn’t even factor in vitamin D from sun exposure when it made its recommendations.

Does that mean I should lay off the sunscreen?

The sun can be a powerful manufacturer of the nutrient: In 15 minutes, a light-skinned person wearing a bathing suit outside in early July will produce 15,000 to 20,000 IUs of Vitamin D.

The body stores excess vitamin D in fat, and some research suggests that it is released as needed. But there’s debate about how well that happens, so the panel members suggest that daily dosing of vitamin D is a better bet.

Besides, even 15 minutes without sunscreen won’t fly with dermatologists. They warn that prolonged exposure to ultraviolet light – either from the sun or in a tanning booth – elevates a person’s risk of developing melanoma, the deadliest form of skin cancer. So, by all means, slather on that sunscreen.”

Do read the whole story.  Here’s a link to that and another good story about Vitamin D.

So, drink your fortified milk and toast to your good health.

Share

Nailing Skin Cancer Awareness

Thursday, August 5th, 2010

We’ve discussed being conscious of sun safety as it applies to things like over-exposure on the arm you rest on the driver’s side window or even through the windshield of your car, exposure in tanning salons, which has been all over the news lately, and even wearing hats on a regular basis. But, per the New York Times article this week, comes a new point of diligence: nail salons.

Picture the polish dryers so prevalent in virtually every salon; don’t they look like little tanning beds for your fingers? Well, there’s a similarity. Apparently, they emit “similar amounts of UV radiation per meter squared, studies show. And like tanning beds, they emit predominantly UVA rays, which penetrate the skin most deeply.”

There are no definitive studies on exact correlation to skin cancer cases, but the advice given is smart: Consider air-drying (indoors.)

Share

What’s in a name? If it’s “ipi,” a lot!

Friday, June 11th, 2010

What’s in a name? If it’s ipilimumab – or "ipi” for short – it may be the first name associated with prolonged life expectancy for melanoma victims. This new immune stimulator has been making headlines recently for its early success in increasing stage four melanoma survival rates for up to four months. While that might not sounds like a lot, it’s considered highly significant. Dr. Steven O’Day of the Angeles Clinic and Research Institute in Santa Monica, Calif., a lead investigator in the recent melanoma trial explains,

This important because this is a disease where the average survival in these patients is six to nine months, so to increase on average the survival by an additional four months is a very large difference.

And though as Dr. Charles M. Balch, a melanoma expert at Johns Hopkins, said the results of the recent clinical trials are "a single, not a home run,” he added that for this disease, which impacts almost 70,000 Americans a year and growing, "even a single was important”. As further described in The New York Times coverage of ipi,

In a study of patients who had advanced melanoma, those who got an experimental drug lived a median of about 10 months, compared with 6.4 months for those in a control group. After two years, about 23 percent of those who got the drug were alive, compared with 14 percent in the control group.

Lung cancer and melanoma are among the hardest cancers to treat. So the studies are being viewed as significant advances, though far from cures.

Dr. O’Day, who presented the research at this month’s ASCO conference, said no prior large randomized trial in melanoma has been able to demonstrate an improved survival in this type of cancer at all. ascocover

He calls ipilimumab "the light at the end of a long, dark tunnel.”

"These results are exciting because patients with melanoma have few treatment options,” Dr. O’Day said. "After 30 years of failed studies, we finally have an option that shows a significant increase in overall survival, an endpoint that many oncology studies strive for. This new class of inhibitors that overcome T-cell suppression offers hope to melanoma patients and oncologists alike.”

The NY Times article provides a good explanation of how T-cell suppression works to possibly slow tumor growth rate though without yet being able to "put the brakes on”:

Ipilimumab is a more general immune booster. It blocks a protein called CTLA-4 that acts as a brake on T cells, the soldiers of the immune system. It is already also being tested against lung and prostate cancer.

Still, if a tumor does not elicit a strong immune response to begin with, then just keeping the response going longer would not help much, just as lifting one’s foot from the brake usually will not make a car go faster if the accelerator is not pressed.

We at MoleSafe are heartened by this news. As always, we encourage regular and thorough screenings to provide the best line of first defense in preventing melanoma from reaching crisis status. Please contact us at any of our now 6 clinical screening locations.

Share

What's in a name? If it's "ipi," a lot!

Friday, June 11th, 2010

What’s in a name?  If it’s ipilimumab – or “ipi” for short – it may be the first name associated with prolonged life expectancy for melanoma victims.  This new immune stimulator has been making headlines recently for its early success in increasing stage four melanoma survival rates for up to four months. While that might not sounds like a lot, it’s considered highly significant. Dr. Steven O’Day of the Angeles Clinic and Research Institute in Santa Monica, Calif., a lead investigator in the recent melanoma trial explains,

This important because this is a disease where the average survival in these patients is six to nine months, so to increase on average the survival by an additional four months is a very large difference.

And though as Dr. Charles M. Balch, a melanoma expert at Johns Hopkins, said the results of the recent clinical trials are “a single, not a home run,” he added that for this disease, which impacts almost 70,000 Americans a year and growing, “even a single was important”.  As further described in The New York Times coverage of ipi,

In a study of patients who had advanced melanoma, those who got an experimental drug lived a median of about 10 months, compared with 6.4 months for those in a control group. After two years, about 23 percent of those who got the drug were alive, compared with 14 percent in the control group.

Lung cancer and melanoma are among the hardest cancers to treat. So the studies are being viewed as significant advances, though far from cures.

Dr. O’Day, who presented the research at this month’s ASCO conference, said no prior large randomized trial in melanoma has been able to demonstrate an improved survival in this type of cancer at all.  ascocover

He calls ipilimumab “the light at the end of a long, dark tunnel.”

“These results are exciting because patients with melanoma have few treatment options,” Dr. O’Day said. “After 30 years of failed studies, we finally have an option that shows a significant increase in overall survival, an endpoint that many oncology studies strive for. This new class of inhibitors that overcome T-cell suppression offers hope to melanoma patients and oncologists alike.”

The NY Times article provides a good explanation of how T-cell suppression works to possibly slow tumor growth rate though without yet being able to “put the brakes on”:

Ipilimumab is a more general immune booster. It blocks a protein called CTLA-4 that acts as a brake on T cells, the soldiers of the immune system. It is already also being tested against lung and prostate cancer.

Still, if a tumor does not elicit a strong immune response to begin with, then just keeping the response going longer would not help much, just as lifting one’s foot from the brake usually will not make a car go faster if the accelerator is not pressed.

We at MoleSafe are heartened by this news.  As always, we encourage regular and thorough screenings to provide the best line of first defense in preventing melanoma from reaching crisis status.  Please contact us at any of our now 6 clinical screening locations.

Share

The Beginning of the End? Melanoma Drug Trials and Tribulations

Wednesday, February 24th, 2010

This week, The New York Times published a series of three articles about the roller-coaster of excitement and frustrations surrounding a promising new drug therapy for melanoma. The series follows the trials, successes and tribulations of a targeted drug, PLX4032, which is specifically beneficial only to those with a B-RAF gene mutation spurring their cancer.

It’s important and excellent reading.

Dr. Flaherty with clinical trial patient

Dr. Flaherty with clinical trial patient

Randy Williams, 46, who drove 600 miles from his home in Jonesboro, Ark., to the M.D. Anderson Cancer Center in Houston to get the experimental drug, rolled out of bed. "Something’s working,” he thought, "because nothing’s hurting.”

It was a sweet moment, in autumn 2008, for Dr. Keith Flaherty, the University of Pennsylvania oncologist leading the drug’s first clinical trial. A new kind of cancer therapy, it was tailored to a particular genetic mutation that was driving the disease, and after six years of disappointments his faith in the promise of such a "targeted” approach finally seemed borne out. His collaborators at five other major cancer centers, melanoma clinicians who had tested dozens of potential therapies for their patients with no success, were equally elated.

But the titles of each article in the series give away the plot:

After Long Fight, Drug Gives Sudden Reprieve

then

A Roller Coaster Chase for a Cure

and finally:

A Drug Trial Cycle: Recovery, Relapse, Reinvention.

My takeaway:

With no significant change in the treatment of advanced stage melanoma in over twenty years this is a great break through. But it’s not the end. It’s the beginning of the end. With a long road to follow.

Still early detection avoids the need for these treatment and the possibility of treatment failure. So, be vigilant. Check your skin and the skin of the people you love. Reduce your risk factors. See your dermatologist on a regular basis. Have your MoleSafe procedure.

Share

Melanoma Shows no Favorites

Thursday, January 7th, 2010

The wealthy or the poor. African American or Caucasian. Melanoma is non-discriminating. Two news stories this past week showed just how this assassin has no loyalties.

FDR and Melanoma

In a new book, "F.D.R.’s Deadly Secret,” by neurologist Dr. Steven Lomazow, and journalist Eric Fettmann, Franklin D. Roosevelt’s death is hypothesized to have been from melanoma. The authors point out various symptoms and medical/political cover-ups, most specifically a disappearing mole in photos over the years.

The book has served to create additional speculation even if it still has not unshrouded the mystery to the satisfaction of many historians. But it has also served to do what we try to do here at Melanoma Updates as well: increase awareness of the deadly trajectory of late or undiagnosed melanomas.

Equal Opportunity Disease

Other melanoma news this week that is more substantiated was about the disparity in skin cancer diagnoses and deaths among Hispanics and African Americans

While the actual incidents of skin cancers and melanomas are lower, African Americans are more than twice as likely as Caucasians to have a melanoma that had spread “regionally or to distant parts of their bodies” at the time of diagnosis. Based on a study of 41,000 cases of melanoma diagnosed in Florida between 1990 and 2004, 12% of white non-Hispanic patients had advanced cancer by the time they were given a diagnosis, 18 % of Hispanic patients and 26% of black patients were at this later stage, when the cancer had already spread.

Granted, the study was based in sun-drenched Florida, but the study’s authors feel a contributing factor may be that Hispanics and blacks might put off seeing a doctor about melanoma lesions because they’re under the impression it’s a whites-only disease. As written in NewsOK:

They’re mostly right, but not completely: … According to the National Cancer Institute’s online database, 28.9 of every 100,000 white men are diagnosed with melanoma, and 18.7 of every 100,000 for white women. For Hispanic men and women, the rates are 4.7 and 4.6; for blacks, it’s 1.1 and 1. Overall, the median diagnosis age is 59.

But the survival rate for whites has gone from 68 percent in the early 1970s to 92 percent in recent years, the study says. “Such advances, however, have not occurred in other racial and ethnic groups in the United States.

And, as summed up in The New York Times version of the story:

"The simple message is that even though blacks and Hispanics are at lower risk, they can still get melanoma, but there seems to be a lack of awareness, so they’re diagnosed at a later stage,” said Dr. Robert S. Kirsner, the paper’s senior author and vice chairman of dermatology at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

The takeaway? Everyone still has to be vigilant.

Share